Premium
IC‐P2‐123: Increased glutamate/N‐acetylaspartate in the hippocampus after galantamine treatment in Alzheimer's disease
Author(s) -
Penner Jacob,
Rupsingh Raul,
Smith Matthew,
Wells Jennie,
Borrie Michael,
Bartha Robert
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2578
Subject(s) - galantamine , hippocampus , creatine , phosphocreatine , glutamate receptor , metabolite , endocrinology , medicine , neurotransmitter , acetylcholine , chemistry , alzheimer's disease , nuclear magnetic resonance , donepezil , dementia , central nervous system , disease , receptor , energy metabolism , physics
potentially useful for early diagnosis of Alzheimer’s disease (AD) and tracking the efficacy of anti-amyloid therapy. The purpose of this study is to evaluate the utility of our original compound BF-227 and its derivative as PET amyloid-imaging agents. Methods: Total 56 subjects, including normal controls, subjects with mild cognitive impairment (MCI), Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Gerstmann-Straussler-Scheinker disease (GSS), underwent PET studies using [C]BF-227 and [F]FDG. Dynamic PET images were obtained for 60 min after administration of [C]BF-227. The ratio of regional to cerebellar standardized uptake value (SUVR) were calculated as the index of [C]BF-227 retention and regional glucose metabolism. Results: AD patients showed neocortical retention of [C]BF-227. ROC analysis indicated better diagnostic performance of [C]BF-227, in comparison to FDG-PET. SUVR in BF227-PET was negatively correlated with MMSE scores and glucose metabolism in temporal and parietal cortex. Cortical retention of [C]BF-227 was also observed in 66% of MCI subjects including 3 subjects who developed AD during follow-up. DLB patients additionally showed cortical retention of [C]BF-227, however the degree of retention in DLB patients was generally milder than that in AD patients. One GSS patient showed remarkable uptake of [C]BF-227, suggesting the binding of BF-227 to prion plaques. F-labeled BF-227 derivative is currently under investigation. Conclusions: From these findings, we conclude that [C]BF227 PET is useful for early detection of amyloidand prion deposits.